Brokerages Set Kodiak Sciences Inc. (NASDAQ:KOD) PT at $31.14

Shares of Kodiak Sciences Inc. (NASDAQ:KOD) have been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $35.4286.

A number of research analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a report on Friday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kodiak Sciences in a research note on Thursday, January 22nd. Finally, UBS Group lifted their target price on shares of Kodiak Sciences from $50.00 to $80.00 and gave the company a “buy” rating in a report on Friday.

Kodiak Sciences Price Performance

Shares of KOD opened at $37.00 on Friday. Kodiak Sciences has a 52 week low of $1.92 and a 52 week high of $45.60. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -8.98 and a beta of 2.61. The stock’s 50-day moving average price is $25.14 and its 200-day moving average price is $21.98.

Key Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Topline Phase 3 (GLOW2) win for Zenkuda: Kodiak reported that Zenkuda (tarcocimab tedromer) met the primary endpoint in GLOW2, showing a large improvement in diabetic retinopathy severity (62.5% of treated patients achieved ≥2‑step DRSS improvement vs 3.3% for sham) with a 6‑month dosing interval — a result that materially raises the drug’s efficacy and commercial prospects. PR Newswire
• Positive Sentiment: Market reaction: The GLOW2 news triggered large intraday rallies (reports of 50–75%+ moves) as traders repriced KOD for a potential regulatory filing and eventual launch. This surge reflected investor expectations that the program can support a Biologics License Application (BLA) and a valuable ophthalmology franchise. Reuters
• Positive Sentiment: Analyst upgrades and higher price targets: Following the data, UBS raised its price target to $80 with a Buy rating and HC Wainwright reaffirmed Buy while raising its target to $58 — both moves signal increased sell‑side conviction and provide further upside narrative for investors. Benzinga (UBS) TickerReport (HC Wainwright)
• Neutral Sentiment: Regulatory path and next steps: Coverage notes and industry press indicate a likely BLA filing is now the logical next step; timing and FDA interactions remain catalysts but are not guaranteed. Positive data increase probability, but approval and commercial uptake timelines still carry execution risk. BioWorld
• Negative Sentiment: Volatility and hedging activity: There was unusually high put option activity the day of the results (large put volumes vs typical), indicating some traders were hedging or positioning for downside — a sign of elevated speculative interest and potential for sharp intraday reversals. (Options flow reported 3,472 puts vs typical ~256.)
• Negative Sentiment: Today’s pullback amid heavy volume: After the strong rally on the data, the shares have pulled back today on very heavy trading — a common post‑news profit taking and volatility washout that increases short‑term risk despite the fundamentally positive trial news.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its position in shares of Kodiak Sciences by 1,221.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock worth $28,000 after acquiring an additional 916 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Kodiak Sciences during the 4th quarter worth about $29,000. Headlands Technologies LLC grew its position in shares of Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after acquiring an additional 5,815 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Kodiak Sciences during the 4th quarter valued at about $72,000. Finally, Strs Ohio purchased a new position in shares of Kodiak Sciences in the 4th quarter valued at about $87,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.